GENE ONLINE|News &
FDA Approves Roche’s Gazyva for Lupus Nephritis, Bringing New Hope to 1.7 Million Patients Worldwide
About 1.7 million people worldwide live with lupus nephritis, most of whom are women of color in their childbearing years. Image: Roche
The U.S. Food and Drug Administration (FDA) has approved Roche’s anti-CD20 monoclonal antibody Gazyva®/Gazyvaro® (obinutuzumab) for adults with lupus nephritis (LN) who are receiving standard therapy. The approval, announced on October 20, 2025, marks the first anti-CD20 antibody to show complete renal response (CRR) in a randomized phase III trial. It signals a new era in lupus nephritis treatment.
The FDA also approved a 90-minute shortened infusion time for eligible patients after the initial dose. The treatment schedule involves four infusions in the first year. It followed by one infusion every six months. Roche noted that this approval reflects both strong clinical efficacy and a commitment to improving patient convenience and quality of life.
Phase III Data Show Significant Improvement in Kidney Function
The FDA decision was supported by results from the phase II NOBILITY (NCT02550652) and phase III REGENCY (NCT04221477) studies. In the REGENCY trial, 46.4% of patients receiving Gazyva plus standard therapy achieved a complete renal response. It compared with 33.1% for standard therapy alone.
The study also showed meaningful improvements in key biomarkers: higher complement levels. It reduced anti-dsDNA antibodies, lower steroid use, and decreased proteinuria. Safety data were consistent with Gazyva’s existing oncology profile, showing no new safety concerns.
Roche’s Chief Medical Officer and Head of Global Product Development, Dr. Levi Garraway, stated: “Patients who achieve complete renal response are more likely to preserve kidney function and delay or prevent end-stage kidney disease. This approval represents both a scientific and clinical milestone.”
Lupus Nephritis Affects 1.7 Million People, Mostly Women of Color
According to epidemiological data, about 1.7 million people worldwide live with lupus nephritis, most of whom are women of color in their childbearing years. Without timely treatment, one in three patients may progress to end-stage kidney disease, requiring dialysis or transplantation.
Louise Vetter, President and CEO of the Lupus Foundation of America, said: “Lupus nephritis is a serious and potentially life-threatening condition. The chronic pain, fatigue, and anxiety over kidney decline are overwhelming. FDA’s approval of Gazyva brings new hope and the chance to prevent long-term complications like kidney failure.”
Gazyva Received Breakthrough Therapy Designation
Gazyva received Breakthrough Therapy Designation from the FDA in 2019. Roche added that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion. It recommended approval for adults with lupus nephritis. A final decision from the European Commission is expected soon.
Mechanism of Action: Targeting B Cells to Control Autoimmune Kidney Damage
Gazyva (obinutuzumab) is a type II, glycoengineered, humanized monoclonal antibody that binds selectively to CD20, a protein expressed on specific B cells. In lupus nephritis, these pathogenic B cells trigger chronic inflammation, leading to progressive kidney damage.
By depleting these B cells, Gazyva helps reduce immune-driven kidney injury and slow disease progression. This mechanism strengthens its role in lupus nephritis. it also opens new therapeutic directions for other immune-mediated kidney diseases.
Expanding Research in Autoimmune Kidney Disorders
Roche is continuing to expand Gazyva’s clinical program to include systemic lupus erythematosus, membranous nephropathy, idiopathic nephrotic syndrome, and pediatric lupus nephritis.
Gazyva / Gazyvaro is approved in over 100 countries for treating hematologic malignancies. In the United States, Genentech and Biogen developed it together. Roche reaffirmed its commitment to advancing therapies for immune-mediated kidney diseases. This aims to establish precision immunomodulation as a new standard in nephrology care.
Related posts:
Regeneron’s FDA Success with Ebola Treating Antibody Cocktail, Inmazeb, Bodes Well for its COVID-19 Candidate
Roche’s Non-Hodgkin Lymphoma Drug Could See Accelerated Approval By December
Roche’s Newly Approved Companion Diagnostic May Open Treatment Options for HER2-low Patients
Roche’s Lunsumio Lands FDA Approval for Pretreated Follicular Lymphoma
